Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Oklahoma Sen. Markwayne Mullin (R) on Thursday objected to a Democratic resolution demanding the Department of Justice ...

Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...

Note that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

Two Republican senators and a broad bipartisan coalition of funders and nonprofits prevented a 600% increase in taxes levied ...

The move reveals both the power of philanthropic groups to sway legislators and a split in the administration’s coalition.

Disclaimer The CNBC Investing Club Charitable Trust owns shares of Eli Lilly. Questions for Cramer? Call Cramer: 1-800-743-CNBC Want to take a deep dive into Cramer's world? Hit him up!

“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per share in Q1 2025, missing analysts’ consensus estimate of $4.64. Despite this, ...